NCT00014183已完成2 期
A Phase II Study Of ZD1839 (NSC #715055) In Renal Cell Carcinoma Stage IV And Renal Cell Carcinoma Recurrent
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 4
研究概览
简要总结
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer.
PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have recurrent or stage IV kidney cancer.
详细描述
OBJECTIVES:
- Determine the response rate in patients with progressive stage IV or recurrent renal cell cancer treated with ZD 1839.
- Determine the median time to objective progression in these patients receiving this drug.
- Determine the toxic effects of this drug in this patient population.
- Determine if epidermal growth factor receptor expression in tumor tissue correlates with response and survival of these patients.
OUTLINE: This is a multicenter study.
Patients receive oral ZD 1839 daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 8 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and NeckHead and Neck CancerNCT00015964University of Chicago51
已完成
2 期
ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal CancerColorectal CancerNCT00030524The University of Texas Health Science Center at San Antonio
已完成
2 期
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First RelapseBrain and Central Nervous System TumorsNCT00016991Duke University
已完成
2 期
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary TractTransitional Cell Cancer of the Renal Pelvis and UreterUrethral CancerBladder CancerNCT00014144SWOG Cancer Research Network31
已完成
2 期
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyProstate CancerNCT00025116NCIC Clinical Trials Group40